(Q74489921)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11548210%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

review article

1 reference

title

Anti-influenza drugs and neuraminidase inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11548210%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

author name string

N A Roberts

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11548210%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 January 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11548210%20AND%20SRC:MED&resulttype=core&format=json

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques

11 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11548210%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

Spec No

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11548210%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

35-77

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11548210%20AND%20SRC:MED&resulttype=core&format=json

The impact of influenza epidemics on mortality: introducing a severity index.

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Clinical manifestations and consequences of influenza

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Influenza vaccines. A reappraisal of their use.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Immunity to influenza in the elderly

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Effective inhibitors of hemagglutination by influenza virus synthesized from polymers having active ester groups. Insight into mechanism of inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Recent progress in anti-influenza chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Emergence and apparent transmission of rimantadine-resistant influenza A virus in families

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Implications of viral resistance to amantadine in control of influenza A

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

A novel antiviral agent which inhibits the endonuclease of influenza viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Inhibition of influenza virus transcription by 2'-deoxy-2'-fluoroguanosine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

In vivo anti-influenza virus activity of a zinc finger peptide

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

A small percentage of influenza virus M1 protein contains zinc but zinc does not influence in vitro M1-RNA interaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Structure of a bifunctional membrane-RNA binding protein, influenza virus matrix protein M1

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Elucidation of basic mechanistic and kinetic properties of influenza endonuclease using chemically synthesized RNAs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Biochemical studies on capped RNA primers identify a class of oligonucleotide inhibitors of the influenza virus RNA polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Inhibition of influenza viral polymerases by minimal viral RNA decoys

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by liposomally encapsulated antisense phosphorothioate oligonucleotides in MDCK cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Evaluation of the anti-influenza virus activities of 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and its sodium salt

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Biochemistry and clinical applications of ribavirin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Antiviral therapy with small particle aerosols

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Oral ribavirin treatment of influenza A and B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Influenza virus resistance to neuraminidase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

A novel mechanism for the acquisition of virulence by a human influenza A virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

An analysis of the role of neuraminidase in the receptor-binding activity of influenza B virus: the inhibitory effect of Zanamivir on haemadsorption

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Rational design of potent sialidase-based inhibitors of influenza virus replication

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Sialidase inhibitors related to zanamivir: synthesis and biological evaluation of 4H-pyran 6-ether and ketone

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Synthesis of tetrasubstituted bicyclo[3.2.1]octenes as potential inhibitors of influenza virus sialidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Synthesis of a tetrasubstituted bicyclo [2.2.2] octane as a potential inhibitor of influenza virus sialidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

The Pathogenesis of Infections of the Mouse Caused by Virulent and Avirulent Variants of an Influenza Virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase)

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

The low potential for drug interactions with zanamivir

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizerfi

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

PAR2 antagonists-the next generation of anti- inflammatories?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

The impact and cost of influenza in the elderly

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-0348-7784-8_2

10.1007/978-3-0348-7784-8_2

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11548210%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference